Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: Comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist

Coronary flow velocity reserve in patients with type 2 diabetes improved after treatment with temocapril but not with candesartan, suggesting that angiotensin-converting enzyme inhibitor, but not angiotensin II type 1 receptor antagonist, might have beneficial effects on coronary microangiopathy associated with type 2 diabetes.